• ABOUT
  • PIPELINE
  • SCIENCE
  • INVESTORS
  • CAREERS
Voyager_hamburger_close
logo
ABOUT
Overview

Vision, Mission, & Strategy

Management Team

Board of Directors

Core Values

PIPELINE

Overview

• VY7523 for Alzheimer’s

• VY1706 for Alzheimer’s

• APOE Gene Therapy for Alzheimer’s

Patient Resources

Partnerships

SCIENCE

Overview

TRACER Platform

Non-Viral Approaches

Publications & Presentations

Partnerships

INVESTORS

Overview

Press Releases

Events & Presentations

Corporate Governance

Financials

Stock Information

Shareholder Services

CAREERS

Overview

Job Openings

Our Community

Core Values

Benefits

Disclosures

ABOUT

Overview

Vision, Mission, & Strategy

Management Team

Board of Directors

Core Values

PIPELINE

Overview

• VY7523 for Alzheimer’s

• VY1706 for Alzheimer’s

• APOE Gene Therapy for Alzheimer’s

Patient Resources

Partnerships

SCIENCE

Overview

TRACER Platform

Non-Viral Approaches

Publications & Presentations

Partnerships

INVESTORS

Overview

Press Releases

Events & Presentations

Corporate Governance

Financials

Stock Information

Shareholder Services

CAREERS

Overview

Job Openings

Our Community

Core Values

Benefits

Disclosures

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

by s2desi5_voyagertherapeutics | Aug 7, 2023 | Uncategorized

CAMBRIDGE, Mass. , Aug. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics , Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer , Ph.D., M.A., M.Phil .,...

Categories

  • Uncategorized

Recent Posts

  • Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
  • Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
  • Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
  • Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
  • Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics, Inc.   •   75 Hayden Avenue, Lexington, MA 02421   •   857.259.5340    linkedin

© 2026 Voyager Therapeutics, Inc. All rights reserved.   /   Terms of Use   /   Privacy Policy   /   Site by D&CO

Voyager Therapeutics, Inc.
75 Hayden Avenue
Lexington, MA 02421
857.259.5340

linkedin

© 2026 Voyager Therapeutics, Inc., All rights reserved.
Terms of Use   /   Privacy Policy   /   Site by D&CO